Genetics, Immune Response, In-Vivo and Research

LNP formulations produce strong immune responses, data shows

Drug Discovery World

FEBRUARY 15, 2024

The etherna paradigm for cLNP design is ushering in the rapid generation of novel families of delivery systems for not only vaccination but also for in vivo tolerisation for a host of autoimmune diseases.”

Immune Response

Immune Response In-Vivo Vaccination Vaccine

Research partners advance AAV gene therapy for heart disease

Drug Discovery World

AUGUST 7, 2023

Evox Therapeutics has agreed a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, NY, US. The collaboration will work on developing exosome-encapsulated AAV (exoAAV) vectors as a novel gene delivery technology aimed at improving treatments for heart disease.

Gene Therapy

Gene Therapy Gene Research In-Vivo

Q&A with Mark Garner: The golden age of cancer research

Drug Discovery World

JULY 5, 2023

Global Cancer Segment Market Manager at Agilent Technologies, recently sat down with DDW Editor Reece Armstrong to tell us about the developments in the ‘golden age’ of cancer research. MG: I am responsible for Agilent’s cancer segment. RA: What is the current state of the cancer research industry? Mark Garner, PhD.,

Research

Research Protein Scientist Immune Response

Closing the translation gap in oncology drug development

Drug Discovery World

MAY 9, 2023

Jantzen Sperry , PhD, Director of Scientific Operations at Certis Oncology looks at how the adoption of orthotopic PDX models can elevate the impact of cancer research and improve translation in oncology drug development. Mice have long been heroes of preclinical cancer research. Cancer is far more complex than the sum of its parts.

Development

Development Drugs In-Vivo Clinical Trials

Fighting viruses is as easy as breathing

The Pharma Data

APRIL 8, 2022

Now, new research from the Wyss Institute at Harvard University has revealed that this constant pattern of stretching and relaxing does even more – it generates immune responses against invading viruses. a Wyss Technology Development Fellow at the Institute. a Wyss Technology Development Fellow at the Institute.

Immune Response

Immune Response In-Vivo Genetic Analysis Research

Using single-cell technology to create human antibody-based therapeutics

Drug Discovery World

FEBRUARY 6, 2023

This is part of why patients in trials and the clinic can experience severe toxicity and adverse events, reject their therapy with an immune response, or completely fail to respond to treatment. DDW’s Megan Thomas caught up with Wyatt McDonnell, CEO and co-founder of Infinimmune. This has consequences for safety and efficacy.

Antibody

Antibody Immune Response Genome Genomics

Verily – Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis

Delveinsight

FEBRUARY 11, 2021

Verily collaborates with Janssen to launch COVID-19 immune response study. Verily is partnering with Johnson & Johnson’s Janssen division to witness the body’s earliest immune responses to a coronavirus infection, with people participating in the research from within their homes. .

Gene Therapy

Gene Therapy Gene Immune Response In-Vivo

A backpack full of multiple sclerosis therapy

The Pharma Data

APRIL 22, 2023

A key driver of MS is the sudden inflammation of nerves caused by so-called myeloid cells of the “innate” immune system in vulnerable regions of the brain and spinal cord, which together form the central nervous system (CNS). million individuals that currently have to live with the disease.

Immune Response

Immune Response Engineer In-Vivo Containment

How mice with humanised immune systems are advancing cell-based immunotherapy

Drug Discovery World

JULY 22, 2022

As a result, researchers are striving to continually improve immuno-oncology approaches using the patient’s own immune cells to combat tumours. Going beyond the limits of immune checkpoint inhibitors (ICIs). However, adverse effects such as cytokine release syndrome (CRS) and neurotoxicity still occur.

In-Vivo

In-Vivo Engineer In-Vitro Medicine

Taking an ‘upside-down’ approach to mRNA delivery

pharmaphorum

JANUARY 17, 2023

Research into mRNA dates back to the 1970s, but with the approval of both Moderna and BioNTech/Pfizer’s vaccines, this approach has finally been validated. Once its potential as a means of stimulating an immune response had been established, attention quickly turned to where else the technology could provide a therapeutic solution.

Vaccination

Vaccination Vaccine In-Vivo In-Vitro

The evolution of assays for immuno-oncology research

Drug Discovery World

FEBRUARY 15, 2023

Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. A healthy immune system is naturally primed to eliminate malignant and abnormal cells through a synchronised and dynamic interplay between adaptive and innate immunity.

Research

Research In-Vitro In-Vivo Development

The challenges and trends of cell & gene therapies

Drug Discovery World

SEPTEMBER 6, 2022

Speaking about emerging opportunities, Carlo Russo, CEO of Genenta, says that whilst “immuno-oncology treatment has been very successful in treating patients suffering from blood cancer,” its success has been limited “by the durability of the responses”. billion, compared to $19.9 million price point per dose.

Gene Therapy

Gene Therapy Gene Manufacturing Medicine

Delivering on the promise of gene editing

Drug Discovery World

DECEMBER 15, 2022

As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific. Early phase clinical trials for gene editing therapies. In one example, Choi et al.

Gene Editing

Gene Editing Gene In-Vivo Genome

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Antibody drug conjugates (ADCs) This session will include three presentations, two clinical updates, two poster highlights, and two luncheon presentations.

Antibody

Antibody Engineer Protein Scientist

Tezepelumab granted Priority Review by U.S. FDA

The Pharma Data

JULY 8, 2021

executive vice president of Research and Development at Amgen. Many patients with severe asthma have an inadequate response to currently available biologics and oral corticosteroids and thus fail to achieve asthma control.(2,6,9) Amgen (NASDAQ:AMGN) announced that the U.S. Reese, M.D., About Severe Asthma.

Allergies

Allergies Trials In-Vivo Medicine

Clinical Research Informer

LNP formulations produce strong immune responses, data shows

Research partners advance AAV gene therapy for heart disease

Trending Sources

Q&A with Mark Garner: The golden age of cancer research

Closing the translation gap in oncology drug development

Fighting viruses is as easy as breathing

Using single-cell technology to create human antibody-based therapeutics

Verily – Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis

A backpack full of multiple sclerosis therapy

How mice with humanised immune systems are advancing cell-based immunotherapy

Taking an ‘upside-down’ approach to mRNA delivery

The evolution of assays for immuno-oncology research

The challenges and trends of cell & gene therapies

Delivering on the promise of gene editing

What to expect from PEGS Europe 2023: Day 1

Tezepelumab granted Priority Review by U.S. FDA

Stay Connected